You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News on molecular markers used to guide cancer treatment, assess prognosis, or detect relapse.
A Phase II trial conducted in China also showed that the HER2-targeting TKI was safe and tolerable in patients with previously treated HER2-positive advanced NSCLC.
The analysis suggested survival and other benefits for breast cancer patients with BRCA1/2 mutations who were aware of their germline risk before diagnosis.
The study will evaluate the safety, tolerability and clinical activity of JSI-1187 in patients with relapsed, refractory solid tumors containing mutations in the MAPK pathway.
The approval will make Merck and AstraZeneca's Lynparza available to patients in the EU who have not progressed after 16 weeks on platinum-based chemotherapy.
The companies will work together to bring Guardant360 through regulatory approval and commercialize it as a CDx for Janssen's amivantamab.
Despite recognition among drugmakers, researchers, and regulators of the need to diversify precision oncology trials, few Black and Hispanic patients are included in studies.
The Quantum Leap-sponsored I-SPY 2 trial will evaluate Byondis' antibody-drug conjugate SYD985 against standard of care for HER2-low, early-stage breast cancer.
Repotrectinib is an investigational drug intended for the treatment of patients with advanced solid tumors harboring ROS1, NTRK1-3, or ALK molecular rearrangements.
Enhertu, or trastuzumab deruxtecan, will also receive accelerated assessment by the European Medicines Agency's Committee for Medicinal Products for Human Use.
A Myriad Genetics-funded team found that an 86-SNV polygenic score could modify breast cancer risk in women with pathogenic mutations in cancer risk genes.